TCGA-97-8175-01A-11R-2287-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 55
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.510
- INFLAMMATORY_RESPONSE+0.420
- INTERFERON_GAMMA_RESPONSE+0.410
- IL6_JAK_STAT3_SIGNALING+0.370
- TNFA_SIGNALING_VIA_NFKB+0.350
- PROTEIN_SECRETION+0.330
- HYPOXIA+0.300
- ALLOGRAFT_REJECTION+0.280
- COAGULATION+0.270
- COMPLEMENT+0.270
Top 10 suppressed
- MYC_TARGETS_V2-0.540
- E2F_TARGETS-0.440
- G2M_CHECKPOINT-0.400
- MYC_TARGETS_V1-0.370
- UNFOLDED_PROTEIN_RESPONSE-0.270
- MITOTIC_SPINDLE-0.250
- WNT_BETA_CATENIN_SIGNALING-0.250
- MYOGENESIS-0.240
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.180
- FATTY_ACID_METABOLISM-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-02219 | — | cohortA1 | 0.856 |
| 2 | DRR168509 | — | — | 0.829 |
| 3 | C3N-02242 | — | cohortA1 | 0.825 |
| 4 | TCGA-MT-A67F-01A-11R-A30B-07 | — | — | 0.824 |
| 5 | DRR168557 | — | — | 0.823 |
| 6 | SRR934976 | — | — | 0.814 |
| 7 | SJBT031351_D1.RNA-Seq | EPN | Supratentorial EPN | 0.813 |
| 8 | C3N-03765 | — | cohortA1 | 0.812 |
| 9 | BS_BC936YNZ | pilocytic astrocytoma | — | 0.805 |
| 10 | BS_PK18H7E7 | low-grade glioma | — | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.180 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |